menu
    • menu
    [{"orgOrder":0,"company":"Hiroshima University","sponsor":"Three Peace Co., Ltd., Japan","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Fucoidan","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Hiroshima University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hiroshima University \/ Three Peace Co., Ltd., Japan","highestDevelopmentStatusID":"1","companyTruncated":"Hiroshima University \/ Three Peace Co., Ltd., Japan"},{"orgOrder":0,"company":"Hi-Q Marine Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fucoidan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Hi-Q Marine Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hi-Q Marine Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hi-Q Marine Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinova Pty Ltd","sponsor":"Nutrasource | University of South Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fucoidan","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Marinova Pty Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marinova Pty Ltd \/ Nutrasource | University of South Carolina","highestDevelopmentStatusID":"1","companyTruncated":"Marinova Pty Ltd \/ Nutrasource | University of South Carolina"},{"orgOrder":0,"company":"VISUfarma","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VISUfarma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"VISUfarma \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for Fucoidan

    Menu

    Fucoidan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            VISUfarma

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Ectoine,Fucoidan

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Strengthens its Ophthalmology Business with Acquisition of VISUfarma

                            Details : The acquisition of VISUfarma, with its broad portfolio of innovative eye health products, including Xailin Ectoine, aligns with Lupin's strategy to expand its European business.

                            Product Name : Xailin Ectoine

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 29, 2025

                            Lead Product(s) : Hyaluronic Acid,Ectoine,Fucoidan

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Marinova Pty Ltd

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Marinova Pty Ltd

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Nutrasource | University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inflammatory and Immune Response After High Intensity Exercise

                            Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 14, 2022

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Nutrasource | University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hi-Q Marine Biotech

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hi-Q Marine Biotech

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squam...

                            Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hiroshima University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hiroshima University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Three Peace Co., Ltd., Japan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of a Supplement Containing Fucoidan on Basal Body Temperature

                            Details : Fucoidan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 21, 2011

                            Lead Product(s) : Fucoidan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Three Peace Co., Ltd., Japan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth